Although there are currently no studies demonstrating the role of 68Ga-Pentixafor in cervical cancer, it appears that CXCR4-targeted imaging could potentially be used to prognosticate patients as well as to select patients who may benefit from therapies targeting CXCR4. Here, CXCR4 is linked to cervical carcinoma.